The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
Beahrs, O. H., & Henson, D. E. (1992) · Medical Entomology and Zoology · Cited by 2,460
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Self-citationA DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Cited by
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
Glickman, M. H., & Ciechanover, A. (2002) · Physiological Reviews · doi:10.1152/physrev.00027.2001 · Cited by 4,237
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Self-citationThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Prognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999
Bostwick, D. G., Grignon, D. J., Hammond, M. E. H., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,239
Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement 1999
Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., Hammond, M. E. H., Henson, D. E., Hutter, R. V. P., Nagle, R. B., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0979-pficc · Cited by 1,230
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation
le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., Anile, C., Maira, G., Mercatelli, N., Ciafrè, S. A., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601790 · Cited by 815
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Molecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002) · Nature Medicine · doi:10.1038/nm762 · Cited by 701
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells
Sutterlüty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Müller, U., & Krek, W. (1999) · Nature Cell Biology · doi:10.1038/12027 · Cited by 700
Regulation of the Cdk inhibitor p27 and its deregulation in cancer
Slingerland, J., & Pagano, M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<10::aid-jcp2>3.0.co;2-i · Cited by 695
Self-citationPhosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1
Vlach, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5334 · Cited by 688
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S. B., Lam, E. W.-F., Burgering, B. M. T., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9138-9148.2000 · Cited by 617
American Joint Committee on Cancer prognostic factors consensus conference: Colorectal working group
Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., & Fielding, L. P. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · Cited by 599
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
Montagnoli, A., Fiore, F., Eytan, E., Carrano, A. C., Draetta, G. F., Hershko, A., & Pagano, M. (1999) · Genes & Development · doi:10.1101/gad.13.9.1181 · Cited by 597
Self-citationLloyd, R. V., Erickson, L. A., Jin, L., Kulig, E., Qian, X., Cheville, J. C., & Scheithauer, B. W. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65277-7 · Cited by 593
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Skp2 is oncogenic and overexpressed in human cancers
Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., & Krek, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081474898 · Cited by 505
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.105 · Cited by 489
Li, B., & Dou, Q. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070047997 · Cited by 446
Cell-cycle inhibitors: three families united by a common cause
Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 431
Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816365 · Cited by 429
Cell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388
Deregulated degradation of the cdk inhibitor p27 and malignant transformation
Bloom, J., & Pagano, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00098-6 · Cited by 374
Self-citationKolluri, S. K., Weiss, C., Koff, A., & Gottlicher, M. (1999) · Genes & Development · doi:10.1101/gad.13.13.1742 · Cited by 364
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., & Coffer, P. J. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108084 · Cited by 363
Regulation of the cell cycle by SCF-type ubiquitin ligases
NAKAYAMA, K., & NAKAYAMA, K. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.02.010 · Cited by 360
Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins
Gurrieri, C., Capodieci, P., Bernardi, R., Scaglioni, P. P., Nafa, K., Rush, L. J., Verbel, D. A., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh043 · Cited by 334
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
Tsihlias, M., Kapusta, M., & Slingerland, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.401 · Cited by 319
Meiners, S., Heyken, D., Weller, A., Ludwig, A., Stangl, K., Kloetzel, P.-M., & Krüger, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301032200 · Cited by 318
Tomoda, K., Kubota, Y., Arata, Y., Mori, S., Maeda, M., Tanaka, T., Yoshida, M., Yoneda-Kato, N., & Kato, J.-Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104431200 · Cited by 308
Laronga, C., Yang, H.-Y., Neal, C., & Lee, M.-H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m905616199 · Cited by 304
Cell cycle regulation and anticancer drug discovery
Jingwen, B., Yaochen, L., & Guojun, Z. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2017.0033 · Cited by 302
Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., Gaudin, P. B., Fazzari, M., Zhang, Z.-F., Massague, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.17.1284 · Cited by 300
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder Cancer
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1072 · Cited by 299
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Philipp-Staheli, J., Payne, S. R., & Kemp, C. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5143 · Cited by 293
The INK4a/ARF tumor suppressor: one gene—two products—two pathways
Chin, L., Pomerantz, J., & DePinho, R. A. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01236-5 · Cited by 288
A growth factor-dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression
Boehm, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf343 · Cited by 285
The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
Ciechanover, A., Orian, A., & Schwartz, A. L. (2000) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(2000)77:34+<40::aid-jcb9>3.0.co;2-6 · Cited by 282
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Role of the F-box protein Skp2 in lymphomagenesis
Latres, E., Chiarle, R., Schulman, B. A., Pavletich, N. P., Pellicer, A., Inghirami, G., & Pagano, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041475098 · Cited by 279
Self-citationRepression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc
Yang, W., Shen, J., Wu, M., Arsura, M., FitzGerald, M., Suldan, Z., Kim, D. W., Hofmann, C. S., Pianetti, S., Romieu-Mourez, R., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204245 · Cited by 277
Multiple functions of p27Kip1 and its alterations in tumor cells: a review
Sgambato, A., Cittadini, A., Faraglia, B., & Weinstein, I. B. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<18::aid-jcp3>3.0.co;2-s · Cited by 276
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
American Joint Committee on Cancer Prognostic Factors Consensus Conference
Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E., & Murphy, G. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11<2436::aid-cncr35>3.0.co;2-# · Cited by 266
Modes of regulation of ubiquitin-mediated protein degradation
Kornitzer, D., & Ciechanover, A. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200001)182:1<1::aid-jcp1>3.0.co;2-v · Cited by 258
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Signoretti, S., Marcotullio, L. D., Richardson, A. L., Ramaswamy, S., Isaac, B. M., Rué, M., Monti, F., Loda, M. F., & Pagano, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15795 · Cited by 257
Self-citationRetractedOverexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression
Radeva, G., Petrocelli, T., Behrend, E., Leung-Hagesteijn, C., Filmus, J., Slingerland, J., & Dedhar, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13937 · Cited by 257
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
The Retinoblastoma Protein Pathway in Cell Cycle Control and Cancer
Bartek, J., Bartkova, J., & Lukas, J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3776 · Cited by 254
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Tanaka, K., Kondoh, N., Shuda, M., Matsubara, O., Imazeki, N., Ryo, A., Wakatsuki, T., Hada, A., Goseki, N., Igari, T., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00026-6 · Cited by 47
Waku, T., Katayama, H., Hiraoka, M., Hatanaka, A., Nakamura, N., Tanaka, Y., Tamura, N., Watanabe, A., & Kobayashi, A. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00010-20 · Cited by 42
The fine-tuning of proteolytic pathways in Alzheimer’s disease
Cecarini, V., Bonfili, L., Cuccioloni, M., Mozzicafreddo, M., Angeletti, M., Keller, J. N., & Eleuteri, A. M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2238-6 · Cited by 21
Metadata
- Authors
- Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M.
- Venue
- Nature Medicine
- Published
- 1997-02
- Volume
- 3
- Issue
- 2
- Pages
- 231-234
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2021457628
- Cited by
- 1,031
- References
- 19
- FWCI
- 35.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.